Date: 2014-09-04
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on September 5-9 in Washington DC
Company: Nosopharm (France)
Product: odilorhabdins (NOSO-95)
Action
mechanism: NOSO-95 is a first-in-class antibacterial molecule, the first member of the new Odilorhabdin class. It was discovered from a bacteria of the genus Xenorhabdus. NOSO-95 is active against the multi-resistant gram-negative pathogens of most concern: Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Pseudomonas aeruginosa and Acinetobacter baumannii. It demonstrated an in vitro and in vivo therapeutic proof-of-concept, thus supporting its high potential to cure life-threatening hospital-acquired infections. Currently, NOSO-95 is undergoing a lead optimization program to help it progress into IND-enabling studies.
Disease:
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On September 4, 2014, Nosopharm, a French specialist in the research and development of new anti-infective drugs, announced the presentation of in vitro and in vivo scientific data for a novel antibacterial class, Odilorhabdins at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on September 5-9 in Washington DC. Philippe Villain-Guillot, CEO of Nosopharm, will deliver a presentation entitled ‘Odilorhabdins: A new class of antibiotics acting against gram-negative pathogens’, which forms a part of the symposium (session 046) ‘Time for a revival of natural products?’ Odilorhabdin was discovered and developed by Nosopharm as part of a three-year program (OOPERA: Odilorhabdin: Preclinical optimization and study to combat antibiotic resistance) that began in 2013 with €1.6 million ($ 2.2 million) project funding. Nosopharm uses its own biotechnological platform, which has a well-established track record in antimicrobial discovery. The Odilorhabdin work is based on the medicinal mining of the bacterial genera Xenorhabdus and Photorhabdus. This novel antibacterial class is currently at the preclinical stage. The presentation targets physicians, clinicians, academic and industrial researchers, opinion leaders and business developers. The content covers Xenorhabdus and Photorhabdus: a promising bioresource for antibiotics, followed by an overview of Odilorhabdins, including their in vitro and in vivo antibacterial activity, chemical structures and a summary of their mode of action. Nosopharm is poised to collaborate with key pharmaceutical partners to develop the drug. “Our presentation at ICAAC is also a launchpad for future partner discussions,” said Philippe Villain-Guillot. “Our next objective is an R&D (preclinical and clinical) and commercialization partnership with a biotech or a pharma company by mid-2015. We welcome a broad range of enquiries from within the industry.”
